TY - JOUR

T1 - Defining the clinical course of multiple sclerosis

T2 - The 2013 revisions

AU - Lublin, Fred D

AU - Reingold, Stephen C

AU - Cohen, Jeffrey A

AU - Cutter, Gary R

AU - Sørensen, Per Soelberg

AU - Thompson, Alan J

AU - Wolinsky, Jerry S

AU - Balcer, Laura J

AU - Banwell, Brenda

AU - Barkhof, Frederik

AU - Bebo, Bruce

AU - Calabresi, Peter A

AU - Clanet, Michel

AU - Comi, Giancarlo

AU - Fox, Robert J

AU - Freedman, Mark S

AU - Goodman, Andrew D

AU - Inglese, Matilde

AU - Kappos, Ludwig

AU - Kieseier, Bernd C

AU - Lincoln, John A

AU - Lubetzki, Catherine

AU - Miller, Aaron E

AU - Montalban, Xavier

AU - O'Connor, Paul W

AU - Petkau, John

AU - Pozzilli, Carlo

AU - Rudick, Richard A

AU - Sormani, Maria Pia

AU - Stüve, Olaf

AU - Waubant, Emmanuelle

AU - Polman, Chris H

N1 - © 2014 American Academy of Neurology.

PY - 2014/7

Y1 - 2014/7

N2 - Accurate clinical course descriptions (phenotypes) of multiple sclerosis (MS) are important for communication, prognostication, design and recruitment of clinical trials, and treatment decision-making. Standardized descriptions published in 1996 based on a survey of international MS experts provided purely clinical phenotypes based on data and consensus at that time, but imaging and biological correlates were lacking. Increased understanding of MS and its pathology, coupled with general concern that the original descriptors may not adequately reflect more recently identified clinical aspects of the disease, prompted a re-examination of MS disease phenotypes by the International Advisory Committee on Clinical Trials of MS. While imaging and biological markers that might provide objective criteria for separating clinical phenotypes are lacking, we propose refined descriptors that include consideration of disease activity (based on clinical relapse rate and imaging findings) and disease progression. Strategies for future research to better define phenotypes are also outlined.

AB - Accurate clinical course descriptions (phenotypes) of multiple sclerosis (MS) are important for communication, prognostication, design and recruitment of clinical trials, and treatment decision-making. Standardized descriptions published in 1996 based on a survey of international MS experts provided purely clinical phenotypes based on data and consensus at that time, but imaging and biological correlates were lacking. Increased understanding of MS and its pathology, coupled with general concern that the original descriptors may not adequately reflect more recently identified clinical aspects of the disease, prompted a re-examination of MS disease phenotypes by the International Advisory Committee on Clinical Trials of MS. While imaging and biological markers that might provide objective criteria for separating clinical phenotypes are lacking, we propose refined descriptors that include consideration of disease activity (based on clinical relapse rate and imaging findings) and disease progression. Strategies for future research to better define phenotypes are also outlined.

KW - Clinical Trials as Topic

KW - Consensus

KW - Humans

KW - Multiple Sclerosis

KW - Societies, Medical

U2 - 10.1212/WNL.0000000000000560

DO - 10.1212/WNL.0000000000000560

M3 - Review

C2 - 24871874

VL - 83

SP - 278

EP - 286

JO - Neurology

JF - Neurology

SN - 0028-3878

IS - 3

ER -